Abstract 5769
Background
Information about chemotherapy is complex. Access to information prior to treatment enables patients to gain a better understanding of their condition, lessen their concerns and enables them to make informed choices about treatment. Traditionally chemotherapy education was provided by oncology clinical nurse specialists (CNS) on an individual basis to patients before they started chemotherapy. Increasing numbers of patients and reduced staff resources lead to problems maintaining service. The Irish Cancer Society’s Daffodil Centres are committed to quality improvement across cancer services available to those affected by cancer. Mater Misericordiae University Hospital (MMUH) and the Irish Cancer Society’s Daffodil Centre collaborated on a group chemotherapy initiative in 2012 initiated in response to a high demand for education services. After a successful pilot the programme is now running in 8 hospitals across Ireland. In 2018 342 group education sessions were held with 1713 attendees.
Methods
The Cancer Nurse in the Daffodil Centre facilitates this programme using educational tools including a specially produced audiovisual support (DVD) and short oral and practical demonstrations to assist different learning styles. To conclude the CNS meets with the patients to discuss their individual plan. All attendees are asked to complete an evaluation form which is inputted into a database and the results collated.
Results
1217 completed the evaluation out of 1713 attendees. A number of themes emerged including: • Welcoming • Good information • Allayed concerns • Empowerment. Acknowledgement of the expertise of the nurse and other allied healthcare professionals who present at the session – medical social workers and dietitians.
Conclusions
Overall satisfaction levels were very high in the programme including the information and content on the DVD and the information received and the way it was explained by the nurse. Of those who left comments they were very positive about the experience and for the opportunity to attend. By attending the session patients and their relative/friends were made to feel welcome. Their knowledge of chemotherapy and its side effects were greatly increased and their fears of commencing treatment were in many ways alleviated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract